Antiphospholipid Syndrome (APS), sometimes known as Hughes Syndrome, is a systemic autoimmune disorder characterized by the persistent presence of specific autoantibodies, known as antiphospholipid antibodies (aPL), and a predisposition to thrombotic events and/or pregnancy-related complications. It can exist as a primary condition or secondary to other autoimmune diseases, most commonly Systemic Lupus Erythematosus (SLE). Understanding its multifaceted nature is crucial for timely diagnosis and effective management.
Clinical Features
The clinical presentation of APS is diverse, but its hallmark features fall into two main categories: vascular thrombosis and obstetric morbidity.
1. Vascular Thrombosis: This is the most common manifestation of APS and can affect virtually any part of the circulatory system.
- Venous Thromboembolism (VTE): This is the most frequent thrombotic event. It typically presents as a Deep Vein Thrombosis (DVT), most often in the lower limbs, causing pain, swelling, redness, and warmth. A portion of the DVT can break off and travel to the lungs, causing a potentially life-threatening Pulmonary Embolism (PE), characterized by sudden chest pain, shortness of breath, and cough.
- Arterial Thrombosis: Arterial clots are also common and can lead to severe consequences. The most frequent manifestation is an ischemic stroke or a transient ischemic attack (TIA), often occurring in younger individuals (under 50) without traditional cardiovascular risk factors. Other arterial events include myocardial infarction (heart attack), peripheral artery occlusions, and thrombosis affecting organs like the kidneys or spleen.
- Small Vessel Thrombosis (Microvascular): Clots can form in the smallest blood vessels, leading to a range of symptoms. This can manifest as livedo reticularis (a purplish, net-like skin discoloration), skin ulcers, digital gangrene, and organ damage due to microthrombi, particularly in the kidneys (APS nephropathy).
2. Obstetric Morbidity: APS is a leading cause of recurrent pregnancy loss and other pregnancy-related complications due to thrombosis and inflammation within the placenta.
- Recurrent Early Miscarriages: Defined as three or more consecutive, unexplained pregnancy losses before the 10th week of gestation.
- Late Fetal Loss: The death of a morphologically normal fetus at or after the 10th week of gestation.
- Premature Birth: Delivery before 34 weeks of gestation due to severe pre-eclampsia, eclampsia, or recognized features of placental insufficiency (e.g., intrauterine growth restriction).
3. Non-Criteria Manifestations: Patients with APS may also present with other clinical signs that are strongly associated with the syndrome but are not part of the formal diagnostic criteria. These include moderate thrombocytopenia (low platelet count), heart valve disease (e.g., Libman-Sacks endocarditis), cognitive dysfunction (“brain fog”), headaches, seizures, and transverse myelitis.
Investigations and Diagnosis
The diagnosis of APS requires a combination of clinical events and persistent laboratory evidence of antiphospholipid antibodies. The internationally recognized Sapporo (and later, revised Sydney) classification criteria are used. A definitive diagnosis requires at least one clinical criterion (vascular thrombosis or obstetric morbidity) and one laboratory criterion.
Laboratory Criteria: The presence of aPL must be confirmed on at least two separate occasions, a minimum of 12 weeks apart, to ensure they are persistent and not transient antibodies related to an infection or medication. The three standard laboratory tests are:
- Lupus Anticoagulant (LA) Test: This is a functional, coagulation-based assay. Despite its name, it is a prothrombotic antibody that paradoxically prolongs clotting time in in vitro laboratory tests like the aPTT. The presence of LA is the strongest predictor of future thrombotic events.
- Anticardiolipin Antibodies (aCL): These are detected via an enzyme-linked immunosorbent assay (ELISA). The test measures both IgG and IgM isotypes, with moderate-to-high titers being clinically significant.
- Anti-β2-Glycoprotein I Antibodies (aβ2GPI): This ELISA test detects antibodies directed against β2-glycoprotein I, a plasma protein that is believed to be the primary antigen for aPL. Both IgG and IgM isotypes are measured.
Patients positive for all three antibody types (LA, aCL, and aβ2GPI) are referred to as “triple positive” and are considered to be at the highest risk for thrombosis and pregnancy complications.
Management
Management strategies are tailored to the patient’s clinical presentation and risk profile, with the primary goal of preventing new thrombotic events.
- Asymptomatic Individuals with aPL: For individuals who have tested positive for aPL but have no history of thrombosis or pregnancy loss, management focuses on aggressive risk factor modification. This includes smoking cessation, managing hypertension and hyperlipidemia, weight control, and avoiding estrogen-containing oral contraceptives. Low-dose aspirin may be considered for primary prevention, especially in high-risk (e.g., triple positive) individuals.
- Patients with Thrombotic APS: The cornerstone of treatment for patients who have experienced a thrombotic event is long-term, often lifelong, anticoagulation.
- Standard Therapy: Warfarin (a vitamin K antagonist) is the gold standard treatment. The intensity of anticoagulation is monitored using the International Normalized Ratio (INR), with a target range typically between 2.0 and 3.0.
- Direct Oral Anticoagulants (DOACs): Recent studies have shown that DOACs (e.g., rivaroxaban, apixaban) may be less effective than warfarin in preventing recurrent thrombosis, particularly in high-risk, triple-positive APS patients. Therefore, warfarin remains the preferred agent for this group.
- Obstetric APS: The goal is to improve pregnancy outcomes by preventing placental thrombosis and inflammation. The standard-of-care is combination therapy with:
- Low-Dose Aspirin (LDA): Typically started prior to conception or as soon as pregnancy is confirmed.
- Prophylactic-Dose Heparin: Usually administered as a daily subcutaneous injection of Low-Molecular-Weight Heparin (LMWH), such as enoxaparin. This is started upon confirmation of pregnancy and continued until the postpartum period. This regimen has been shown to increase the live birth rate from approximately 20% to over 70%.
Prognosis
With appropriate diagnosis and diligent management, the prognosis for many patients with APS is generally good in terms of preventing recurrent events and improving quality of life. However, it is a chronic condition that requires lifelong monitoring. The long-term outlook depends on several factors, including the patient’s antibody profile (triple positivity carries a worse prognosis), the type of initial event (arterial events are associated with higher risk), the presence of co-existing autoimmune diseases like SLE, and strict adherence to anticoagulation therapy. Despite treatment, there remains a persistent lifetime risk of recurrent thrombosis. For obstetric APS, therapeutic intervention has dramatically improved the prognosis for a successful pregnancy.
Complications
Both the disease itself and its treatment can lead to significant complications.
- Recurrent Thrombosis: This is the primary complication and can occur even while on anticoagulation, sometimes necessitating a higher INR target or alternative treatment strategies.
- Catastrophic Antiphospholipid Syndrome (CAPS): This is a rare (<1% of patients) but life-threatening complication characterized by widespread small vessel thrombosis leading to rapid multi-organ failure. It has a high mortality rate and requires immediate, aggressive treatment with high-dose anticoagulation, corticosteroids, and often plasma exchange or intravenous immunoglobulin (IVIG).
- Post-Thrombotic Syndrome: Following a DVT, patients may develop chronic leg swelling, pain, and skin changes, which can be debilitating.
- Treatment-Related Complications: The main complication of long-term anticoagulation is bleeding. Patients must be carefully monitored to balance the risk of clotting against the risk of hemorrhage. Long-term heparin use can also be associated with osteoporosis, although this risk is lower with LMWH.
In conclusion, Antiphospholipid Syndrome is a complex and serious autoimmune disorder that requires a high index of suspicion for diagnosis. Its management hinges on a personalized approach centered on anticoagulation and risk reduction, often guided by a multidisciplinary team including a rheumatologist, hematologist, and, for obstetric cases, a maternal-fetal medicine specialist.
References:
- Miyakis, S., Lockshin, M. D., Atsumi, T., Branch, D. W., Brey, R. L., Cervera, R., … & de Groot, P. G. (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4(2), 295-306.
- Garcia, D., & Erkan, D. (2018). Diagnosis and Management of the Antiphospholipid Syndrome. New England Journal of Medicine, 378(21), 2010-2021.
- Pengo, V., Denas, G., Zoppellaro, G., Jose, S. P., Crippa, L., Banzato, A., … & Tripodi, A. (2018). Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 132(13), 1365-1371.
- Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de la Red, G., … & Espinosa, G. (2015). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 74(6), 1011-1018.
- Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., … & Tincani, A. (2019). EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 78(10), 1296-1304.
